Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation

Europace. 2021 Oct 9;23(10):1686. doi: 10.1093/europace/euab219.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Administration, Oral
  • Anticoagulants / adverse effects
  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / diagnosis
  • Atrial Fibrillation* / drug therapy
  • Humans
  • Stroke* / diagnosis
  • Stroke* / etiology
  • Stroke* / prevention & control
  • Vitamin K

Substances

  • Anticoagulants
  • Vitamin K